PHM.MC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:35):

Stats
Today's Volume	58 934.00
Average Volume	38 985.00
Market Cap	514.12M
EPS	€0 ( 2024-04-24 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	262.00
ATR14	€0.0510 (0.18%)

Volume Correlation

Long: 0.16 (neutral)

Short: 0.68 (moderate)

Signal:(61.27) Neutral

Pharma Mar, S.A. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharma Mar, S.A. Correlation - Currency/Commodity

0.58
( weak )

0.39
( neutral )

0.00
( neutral )

0.50
( neutral )

0.37
( neutral )

-0.61
( weak negative )

Pharma Mar, S.A. Financials

Annual	2023
Revenue:	€158.15M
Gross Profit:	€144.86M (91.60 %)
EPS:	€0.0635

Q4	2023
Revenue:	€40.51M
Gross Profit:	€38.06M (93.95 %)
EPS:	€-0.390

Q3	2023
Revenue:	€37.45M
Gross Profit:	€34.31M (91.60 %)
EPS:	€0.0846

Q2	2023
Revenue:	€46.21M
Gross Profit:	€44.32M (95.91 %)
EPS:	€0.280

Financial Reports:

No articles found.

Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.